Selective CK1a Degraders Exert Antiproliferative Activity Against a Broad Range of Human Cancer Cell Lines

Gisele Nishiguchi(St. Jude Children's Research Hospital), Zoran Ranković(St. Jude Children's Research Hospital), Danette L. Daniels(Foghorn Therapeutics (United States)), Yunchao Chang(St. Jude Children's Research Hospital), Lauren G. Mascibroda(St. Jude Children's Research Hospital), Junmin Peng(St. Jude Children's Research Hospital), Anthony A. High(St. Jude Children's Research Hospital), Shilpa Narina(St. Jude Children's Research Hospital), Darcie J. Miller(St. Jude Children's Research Hospital), Sourav Das(St. Jude Children's Research Hospital), Marcus Fischer(St. Jude Children's Research Hospital), Sherif Abdelhamed(University of Washington Bothell), Kristin M. Riching(Promega (United States)), Ryan Hiltenbrand(St. Jude Children's Research Hospital), Jeffery M. Klco(St. Jude Children's Research Hospital), Vibhor Mishra(St. Jude Children's Research Hospital), Marjeta Urh(Promega (United States)), Kevin McGowan(St. Jude Children's Research Hospital), Charles G. Mullighan(St. Jude Children's Research Hospital), Anand Mayasundari(St. Jude Children's Research Hospital), Allister J. Loughran(St. Jude Children's Research Hospital), Guido J.R. Zaman(GlaxoSmithKline (Netherlands)), Anang A. Shelat(St. Jude Children's Research Hospital), Shondra Miller, Jeffrey J. Kooijman, Juan M. Barajas(St. Jude Children's Research Hospital), Sarah P. Young(Duke Medical Center), Elizabeth A. Caine(Promega (United States)), Anup Aggarwal(St. Jude Children's Research Hospital), Zhe Shi(National University of Singapore), Ravi Kalathur(St. Jude Children's Research Hospital)
Figshare
January 1, 2024
Cited by 0


Related Papers